Serum microtubule-associated protein light chain 3 type II levels correlate with aggravation and multi-organ dysfunction in septic patients
Sepsis, a life-threatening response to infection, affects over 50 million people worldwide annually—and kills one in five cases. It’s a complex condition where the body’s immune system overreacts, damaging its own organs. For years, doctors have sought better ways to track sepsis progression and predict outcomes. Now, a 2021 study from researchers at Peking Union Medical College Hospital in Beijing highlights a promising new biomarker: serum levels of microtubule-associated protein light chain 3 type II (LC3b), a key player in autophagy—the cell’s natural “cleanup” process for damaged proteins and organelles.
The Study: What They Did
Led by Dr. Xiao-Ting Wang and colleagues from the Department of Critical Care Medicine, the prospective cohort study enrolled 163 patients admitted to the ICU between June 2019 and August 2020. Participants were split into three groups to reflect different stages of infection and sepsis:
- Infection group: 29 patients with active or suspected infection (not yet septic).
- Septic nonshock group: 40 patients with sepsis (defined by a ≥2-point increase in the Sequential Organ Failure Assessment, or SOFA, score) but no shock.
- Septic shock group: 94 patients with sepsis plus low blood pressure (requiring vasopressors) and high lactate levels (>2 mmol/L)—a sign of severe organ stress.
Within 24 hours of admission, the team collected blood samples to measure LC3b (a marker of autophagy) and two pro-inflammatory cytokines (IL-1b and IL-18, which drive sepsis-related damage). They used enzyme-linked immunosorbent assay (ELISA) kits for these measurements and analyzed data alongside clinical metrics like SOFA scores (organ dysfunction), procalcitonin (infection severity), and 30-day survival.
Key Findings: LC3b Tracks Sepsis Severity
The results revealed a clear trend: LC3b levels dropped as sepsis worsened.
- Infection group: LC3b levels were highest—a sign autophagy was active to fight infection.
- Septic nonshock group: LC3b levels fell significantly.
- Septic shock group: LC3b levels were lowest—suggesting autophagy had become suppressed.
Beyond sepsis stages, the study found:
- Lower inflammation with higher LC3b: Patients with high LC3b had significantly lower levels of IL-1b and IL-18—proof that autophagy helps “cool down” the overactive immune system.
- Worse organ function with lower LC3b: LC3b showed a strong negative correlation with SOFA scores (r = –0.609, P < 0.001). In short: lower LC3b meant more severe organ damage.
- Survivors had higher LC3b: While not statistically significant (likely due to the small sample), survivors tended to have higher LC3b levels than non-survivors—hinting at autophagy’s protective role.
What It Means for Sepsis Care
Autophagy is often called the body’s “cellular janitor.” In early sepsis, it ramps up to clear damaged cells, kill pathogens, and limit inflammation. But as sepsis progresses to shock, autophagy becomes overwhelmed. This suppression is linked to worse outcomes: animal studies show late-stage autophagy loss leads to organ failure and death.
The study supports this idea: LC3b levels mirror autophagy’s protective-to-detrimental shift. High LC3b in mild infection or sepsis suggests the body is coping; low LC3b in septic shock signals the “janitor” has quit—putting organs at risk.
The link between LC3b and inflammation is also critical. Autophagy controls cytokine storms (the over-release of IL-1b/IL-18) by removing inflammation triggers like damaged mitochondria. This is why high LC3b correlated with lower cytokine levels in the study.
Limitations to Consider
Like all research, this study has gaps:
- Single center, small sample: The trial was done at one hospital with 163 patients—too few to rule out bias in patient selection.
- No long-term tracking: The team measured LC3b once at admission. More data is needed to see if LC3b changes with treatment or predicts recovery.
- Confounders unadjusted: Factors like age, medication use, or underlying diseases (e.g., diabetes) could affect LC3b levels but weren’t fully controlled for.
The Takeaway: LC3b as a Potential Sepsis Biomarker
For doctors, the study offers a new tool to add to the sepsis toolkit. Current markers like lactate and procalcitonin track infection and organ stress—but LC3b could fill a gap by measuring autophagy, a key cellular process in sepsis. If larger trials confirm these findings, LC3b might help:
- Early diagnosis: Identify patients at risk of progressing to septic shock.
- Targeted treatment: Guide therapies to restore autophagy in late-stage sepsis.
- Outcome prediction: Estimate risk of organ failure or death.
This study was published in the Chinese Medical Journal in 2021 by Wei Huang, Da-Wei Liu, Guang-Jian Wang, Hong-Min Zhang, Gao-Sheng Zhou, Jing-Jing Liu, and Xiao-Ting Wang from the Department of Critical Care Medicine at Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences. The full study is available at doi.org/10.1097/CM9.0000000000001640
Was this helpful?
0 / 0